[ad_1]
CAMBRIDGE, Mass. – (BUSINESS WIRE) – Apnimed, a clinical-stage pharmaceutical company focused on advancing medications for the treatment of obstructive sleep apnea (OSA) and related disorders, announced today that Larry Miller, MD, chief executive officer, will participate in a fireplace chat to 3rd Evercore ISI HealthCONx Annual Conference, held virtually December 1 to 3, 2020. The presentation is scheduled for Thursday, December 3 from 1:50 pm to 2:10 pm ET.
A live webcast of the presentation will be available in the events section of the Apnimed website. A replay of the presentation will be archived on the company’s website.
Information on obstructive sleep apnea
Obstructive sleep apnea (OSA) is one of the most common and serious sleep disorders and is estimated to affect more than 25 million Americans, although underdiagnosis continues to be a serious problem. OSA is characterized by the partial or complete closure of the upper airways that occurs during sleep, often leading to poor sleep and, in the long term, hypertension, diabetes, cardiovascular disease, stroke, and early mortality. In addition, OSA can compromise work productivity, reduce functional ability and lower quality of life.
Central nervous system-driven sleep-related muscle relaxation is the key neurological problem leading to OSA. In patients with OSA, onset of sleep leads to a reduction in neuromuscular control of the upper airways and corresponding relaxation of the upper airway muscles and tongue. The vast majority of diagnosed patients are prescribed positive air pressure therapy devices such as continuous positive airway pressure or CPAP, but less than half are long-term compliant, leaving a significant population untreated, undertreated and at risk.
About 109 AD
Apnimed’s lead product candidate, AD109, targets neurological control and facilitates activation of the upper airway dilator muscles to keep the airways open during sleep. AD109 is a first-class oral pharmaceutical combination, administered once daily at bedtime, designed to treat patients with OSA across a broad spectrum of disease severity. AD109 combines a selective norepinephrine reuptake inhibitor (atomoxetine) with a new chemical entity (NCE): a selective antimuscarinic (aroxybutynin). The investigational drug is designed to be safe, effective and affordable, addressing the major limitations of current standards of care.
About Apnimed
Apnimed is a clinical-stage pharmaceutical company that works to transform sleep apnea treatment based on a simple idea: patients with obstructive sleep apnea will benefit from treatment with a safe and effective oral medication. Apnimed’s main development program aims at neurological control of the upper airway muscles to keep the airways open during sleep. The drug is administered as convenient once a day before bedtime. Based in Cambridge, Mass., The company is developing a portfolio of new drug therapies for sleep apnea and related disorders. Find out more at Apnimed.com.
Source link
